TY - JOUR
AU - Mawer, E. Barbara
AB - LETTERS TO THE EDITOR 3517 necessarily result in serious complications and could have a potentially treatment, without hypercalcemia, thus permitting a trial of the hor- beneficial effect in progressive breast cancer. mone’s antiproliferative properties. Genaro M. A. Palmieri E. Barbara Mawer University of Tennessee at Memphis Department of Medicine Memphis, Tennessee 38163 Manchester Royal Infirmary Manchester M13 9WL, United Kingdom References References 1. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ. 1997 1. Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. 1981 Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity Influence of the vitamin D-binding protein on the serum concentration of in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1,25-dihydroxyvitamin D3. J Clin Invest. 67:589 –596. 82:118 –122. 2. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ. 1997 2. Stack KM, Palmieri GMA. 1989 1,25 dihydroxyvitamin D in severe immune Serum 1,25-dihydroxyvitamin D may be related to disease activity in breast challenges. Immunol Lett. 23:77. cancer patients with bone metastases. J Clin Endocrinol Metab. 82:118 –122. 3. Eisman JA, Sher E, Suva LJ, Frampton RJ, McLean FL. 1984 1a25-dihy- 3. Stack 
TI - 1,25 Dihydroxyvitamin D and Cancer—Author’s Responsef
JF - Journal of Clinical Endocrinology and Metabolism
DO - 10.1210/jcem.82.10.4288-7
DA - 1997-10-01
UR - https://www.deepdyve.com/lp/oxford-university-press/1-25-dihydroxyvitamin-d-and-cancer-author-s-responsef-i419DRMqYm
SP - 3517
EP - 3517
VL - 82
IS - 10
DP - DeepDyve
ER -